Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Estrogen Receptor Negative|Estrogen Receptor Positive|Glioblastoma|Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Metastatic Renal Cell Cancer|Recurrent Adult Brain Neoplasm|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Lung Carcinoma|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Uterine Corpus Carcinoma|Resectable Hepatocellular Carcinoma|Sarcoma|Stage IA Breast Cancer|Stage IA Ovarian Cancer|Stage IA Uterine Corpus Cancer|Stage IB Breast Cancer|Stage IB Ovarian Cancer|Stage IB Uterine Corpus Cancer|Stage IC Ovarian Cancer|Stage II Uterine Corpus Cancer|Stage IIA Breast Cancer|Stage IIA Lung Carcinoma|Stage IIA Ovarian Cancer|Stage IIB Breast Cancer|Stage IIB Esophageal Cancer|Stage IIB Lung Carcinoma|Stage IIB Ovarian Cancer|Stage IIB Skin Melanoma|Stage IIC Ovarian Cancer|Stage IIC Skin Melanoma|Stage IIIA Breast Cancer|Stage IIIA Esophageal Cancer|Stage IIIA Lung Carcinoma|Stage IIIA Ovarian Cancer|Stage IIIA Skin Melanoma|Stage IIIA Uterine Corpus Cancer|Stage IIIB Breast Cancer|Stage IIIB Esophageal Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Skin Melanoma|Stage IIIB Uterine Corpus Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Skin Melanoma|Stage IIIC Uterine Corpus Cancer|Stage IV Bladder Urothelial Carcinoma|Stage IV Esophageal Cancer|Stage IV Ovarian Cancer|Stage IV Prostate Cancer|Stage IV Skin Melanoma|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer
Interventions: BIOLOGICAL: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Sirolimus
Sponsor: Roswell Park Cancer Institute
Collaborators: National Cancer Institute (NCI)